SHP-1 promoter hypermethylation would also lead to its downregulation with consequent activated phosphorylation of STAT3.37 We speculate the combined STAT3 and DNMT inhibition is a reasonable treatment strategy in STAT3-activated cancers. Here, STAT3 is linked to cancer.